 CAMBRIDGE, Mass.--BUSINESS WIRE--Gemini Therapeutics, Inc. Nasdaq: GMTX, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration AMD, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November: Stifel 2021 Virtual Healthcare Conference Date: Monday, November 15, 2021 Time: 8:40 AM ET Jefferies London 